Evidence map›Paper›PMID 34750784›Full record

ArticleThe patient2022

Women's Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy.

Tatyana Kushner, Angelyn Fairchild, F Reed Johnson, Bruce E Sands, Uma Mahadevan, Sreedhar Subramanian, Ashwin Ananthakrishnan, Christina Ha, Meenakshi Bewtra

Abstract read
PubMed Publisher
In one paragraph

Article in The patient, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Tatyana Kushner *Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Angelyn Fairchild *Duke Clinical Research Institute, Duke University, Durham, NC, USA.
F Reed JohnsonDuke Clinical Research Institute, Duke University, Durham, NC, USA.
Bruce E SandsDivision of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Uma MahadevanUniversity of California, San Francisco, CA, USA.
Sreedhar SubramanianDepartment of Gastroenterology, University of Liverpool, Liverpool, UK.
Ashwin AnanthakrishnanDepartment of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
Christina HaDivision of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Meenakshi BewtraDivision of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA. mbewtra@pennmedicine.upenn.edu.ORCID 0000-0002-6489-7043
Duke University · USIcahn School of Medicine at Mount Sinai · USCedars-Sinai Medical Center · USMassachusetts General Hospital · USPenn Center for AIDS Research · USUniversity of California, San Francisco · USUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWomen with inflammatory bowel disease (IBD) face difficult decisions regarding treatment during pregnancy: while the majority of IBD medications are safe, there is substantial societal pressure to avoid exposures during pregnancy. However, discontinuation of IBD medications risks a disease flare occurring during pregnancy.

objectiveThis study quantified women's knowledge about pregnancy and IBD and their willingness to accept the risks of adverse pregnancy outcomes to avoid disease activity or medication use during pregnancy.

methodsWomen with IBD recruited from four centers completed an online discrete-choice experiment stated-preference study including eight choice tasks and the Crohn's and Colitis Pregnancy Knowledge questionnaire. Random-parameters logit was used to estimate preferences for both the respondent personally and what the respondent thought most women would prefer. We also tested for systematically different preferences among individuals with different demographic and personal characteristics, including IBD knowledge. The primary outcome was the maximum acceptable risk of premature birth, birth defects, or miscarriage that women with IBD were willing to accept to avoid (1) taking an IBD medication or (2) having a disease flare during pregnancy.

resultsAmong 230 respondents, women would accept, on average, up to a 4.9% chance of miscarriage to avoid a disease flare. On average, there were no statistically significant differences in women's preferences for continuing versus avoiding medication in the absence of a flare. However, prior understanding of IBD and pregnancy significantly affected preferences for IBD medication use during pregnancy: women with "poor knowledge" would accept up to a 6.4% chance of miscarriage to avoid IBD medication use during pregnancy, whereas women with "adequate knowledge" would accept up to a 5.1% chance of miscarriage in order to remain on their medication. Respondents' personal treatment preferences did not differ from their assessment of other women's preferences.

conclusionsWomen with IBD demonstrated a strong preference for avoiding disease activity during pregnancy. Knowledge regarding pregnancy and IBD was a strong modifier of preferences for continuation of IBD medications during pregnancy. These findings point to an important opportunity for intervention to improve disease control through education to increase medication adherence and alleviate unnecessary fears about IBD medication use during pregnancy.

Indexed as

Abortion, SpontaneousCrohn DiseaseInflammatory Bowel DiseasesChronic DiseaseFemaleHumansPatient PreferencePregnancySymptom Flare Up

Identifiers

PMID34750784
OpenAlexW3213898873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.